Navigation Links
Techne Announces Resignation Of Chief Financial Officer Gregory Melsen
Date:1/2/2014

MINNEAPOLIS, Jan. 2, 2014 /PRNewswire/ -- Techne Corporation (NASDAQ: TECH) today announced that Gregory J. Melsen will resign from his position as Chief Financial Officer, effective February 3, 2014, to pursue other opportunities.  Mr. Melsen has served as Techne's Chief Financial Officer since 2004.

Techne has begun the process of identifying a successor to Mr. Melsen and expects to announce the appointment of such successor in the coming months.

"I would like to thank Greg for his immense contributions to Techne during the past nine years," stated Charles Kummeth, President and Chief Executive Officer of Techne.  "Greg was instrumental in the recent leadership transition, and the experienced financial team that Greg has put in place will ensure that the current transition is seamless.  On behalf of Techne, I wish Greg all the best for the future."

Mr. Melsen said, "Being Chief Financial Officer of Techne has been a great professional experience, and I look forward to watching the Company continue to execute the strategies that have recently been put into place."

About Techne Corporation

Techne Corporation and Subsidiaries (the Company) are engaged in the development, manufacture and sale of biotechnology products and hematology calibrators and controls. These activities are conducted through the Company's two operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England.

R&D Systems is a specialty manufacturer of biological products. R&D Systems has four subsidiaries: BiosPacific, Inc. (BiosPacific), located in Emeryville, California, Boston Biochem, Inc., located in Cambridge, Massachusetts, Bionostics Holdings Limited (Bionostics), operating in Devens, Massachusetts, and R&D Systems China Co. Ltd., (R&D China), located in Shanghai, China. BiosPacific is a worldwide supplier of biologics to manufacturers of in vitro diagnostic systems and immunodiagnostic kits.  Boston Biochem is a leading developer and manufacturer of ubiquitin-related research products.  Bionostics is a leading supplier of control solutions used in point of care blood glucose and blood gas testing.

R&D China and R&D Europe distribute the Company's biotechnology products. R&D Europe has two subsidiaries: Tocris Holdings Ltd. (Tocris) of Bristol, England and R&D Systems GmbH, a German sales operation. Tocris is a leading supplier of chemical reagents for non-clinical life science research.

Forward-Looking Statements

Certain statements found in this release may constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect the speaker's current views with respect to future events and financial performance and include any statement that does not directly relate to a current or historical fact. Forward-looking statements can generally be identified by the words "believe," "expect," "anticipate" or "intend" or similar words.  The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the integration of new leadership, the introduction and acceptance of new biotechnology and hematology products, the levels and particular directions of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.


'/>"/>
SOURCE Techne Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
2. Techne Corporation Releases Unaudited Fourth Quarter And Fiscal Year 2012 Results
3. Techne Corporation Releases Unaudited Second Quarter And Six Month Fiscal Year 2013 Results
4. Techne Corporation Releases Unaudited Fourth Quarter And Fiscal Year 2013 Results
5. Techne Corporation Releases Unaudited First Quarter Fiscal Year 2014 Results
6. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
7. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
8. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
9. Misonix Announces New Distribution Agreement For Panama
10. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 27, 2017 Summary This ... Bayer and its partnering interests and activities since 2010. ... an in-depth insight into the partnering activity of one of ... company reports are prepared upon purchase to ensure inclusion of ... The report will be delivered in PDF format within ...
(Date:3/27/2017)...  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the ... of common stock in an underwritten public offering under ... Securities and Exchange Commission (the "SEC"). The offering is ... be no assurance as to whether or when the ... size or terms of the offering. Cryoport also expects ...
(Date:3/27/2017)... CHICAGO , March 27, 2017  A ... Educators (AADE) found that Medicare,s Competitive Bidding Program (CBP) ... diabetes testing supplies. The lack of choice forces beneficiaries ... can have dire health consequences. AADE,s ... reports by AADE and others pointing out the inherent ...
Breaking Medicine Technology:
(Date:3/28/2017)... City, NJ (PRWEB) , ... March 28, 2017 ... ... American Camp Association’s Tri-State Camp Conference in Atlantic City March 13-16, was a ... and their team of professional staff discussed strategies for preventing outbreaks among camp ...
(Date:3/28/2017)... Francisco, CA (PRWEB) , ... March 28, 2017 , ... ... treatment, is proud to announce a new blog post about women’s hair loss. Although ... suffer from hair loss as they age. Menopause or genetics can be two reasons ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Thank you to ... on February 8-10. , This event was exclusive to providers and offered an ... The meeting took place at the Manchester Grand Hyatt where attendees gathered for a ...
(Date:3/28/2017)... ... March 28, 2017 , ... “A Prophets Bones”: a thrilling adventure that reveals the ... , “There were things that his parents and teachers had asked of him that he ... he was going to defy the Almighty Creator. There were some who would have felt ...
(Date:3/27/2017)... ... 27, 2017 , ... New patients who have sleep apnea in ... or without a referral. Sleep apnea is often left untreated because patients are not ... and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep apnea ...
Breaking Medicine News(10 mins):